tiprankstipranks
Adynxx, Inc. (ADYX)
OTHER OTC:ADYX
US Market

Adynxx (ADYX) Price & Analysis

60 Followers

ADYX Stock Chart & Stats

$0.02
$0.00(0.00%)
At close: 4:00 PM EST
$0.02
$0.00(0.00%)

ADYX FAQ

What was Adynxx, Inc.’s price range in the past 12 months?
Adynxx, Inc. lowest stock price was $0.01 and its highest was $0.01 in the past 12 months.
    What is Adynxx, Inc.’s market cap?
    Adynxx, Inc.’s market cap is $6.00.
      When is Adynxx, Inc.’s upcoming earnings report date?
      The company’s upcoming earnings report date is not yet available.
      How were Adynxx, Inc.’s earnings last quarter?
      Currently, no data Available
      Is Adynxx, Inc. overvalued?
      According to Wall Street analysts Adynxx, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Adynxx, Inc. pay dividends?
        Adynxx, Inc. pays a Monthly dividend of $6.3 which represents an annual dividend yield of N/A. See more information on Adynxx, Inc. dividends here
          What is Adynxx, Inc.’s EPS estimate?
          Adynxx, Inc.’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Adynxx, Inc. have?
          Adynxx, Inc. has 5,808,000 shares outstanding.
            What happened to Adynxx, Inc.’s price movement after its last earnings report?
            Currently, no data Available
            Which hedge fund is a major shareholder of Adynxx, Inc.?
            Currently, no hedge funds are holding shares in ADYX
            What is the TipRanks Smart Score and how is it calculated?
            Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

              Company Description

              Adynxx, Inc.

              Adynxx, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating and commercializing novel transcription factor decoy technologies to combat pain and inflammatory conditions. Central to its efforts is the AYX platform of transcription factor decoys, which includes brivoligide, currently progressing through Phase II clinical development for reducing post-surgical discomfort. Additionally, AYX2 is a pre-clinical candidate being explored for its potential in treating localized chronic pain. Established in 2007, the company's corporate headquarters are situated in San Francisco, California.
              Similar Stocks
              Company
              Price & Change
              Follow
              PharmaCyte Biotech
              Enveric Biosciences
              PainReform
              GRI Bio
              Popular Stocks